Explore ›
Finding
Finding
decline
Commercially insured patients with intellectual/developmental disabilities and ASCVD were significantly less likely to have pharmacy claims for beta-blockers compared to non-IDD patients (35.8% vs 48.4%), representing a 12.6 percentage point prescribing gap.
| Effect size | adjusted OR 0.65 |
| CI | 95% CI = 0.58-0.73 |
| Comparator | Non-IDD patients with ASCVD in the same commercially insured database (n=790,343) |
| Effect summary | decline; adjusted OR 0.65; CI: 95% CI = 0.58-0.73 |
| Effect modifiers | [{"modifier": "IDD subtype (Down syndrome)", "interaction_p": "", "direction": "amplifies", "stratum_details": "Down syndrome vs autism spectrum disorder: adjusted OR 0.26, 95% CI 0.13-0.51 for beta-blocker use in ASCVD", "plain_language": "Patients with Down syndrome had the lowest beta-blocker prescribing rates of any IDD subtype for ASCVD", "annotation_notes": "Subgroup analysis within IDD patients, with autism spectrum disorder as reference group"}, {"modifier": "IDD subtype (cerebral palsy)", "interaction_p": "", "direction": "amplifies", "stratum_details": "Cerebral palsy vs autism spectrum disorder: adjusted OR 0.53, 95% CI 0.34-0.84 for beta-blocker use in ASCVD", "plain_language": "Patients with cerebral palsy also had significantly lower beta-blocker prescribing rates for ASCVD compared to those with autism spectrum disorder", "annotation_notes": "Subgroup analysis within IDD patients"}] |
Connected entities
Interventions
Outcomes
Source
PMC8009695
Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database